Equities

Taysha Gene Therapies Inc

TSHA:NSQ

Taysha Gene Therapies Inc

Actions
  • Price (USD)2.39
  • Today's Change0.76 / 46.63%
  • Shares traded25.41m
  • 1 Year change+58.80%
  • Beta0.3872
Data delayed at least 15 minutes, as of Nov 12 2024 21:00 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Forecasts data is unavailable for this security.

Consensus recommendation

  • 16-Nov-23
  • 15-Aug-24
  • 19-Sep-24
  • 17-Oct-24
  • 07-Nov-24
Select bar for recommendation details.
Recommendations07-Nov-24
Buy2
Outperform9
Hold0
Sell0
Strong Sell0

Share price forecast in USD

The 11 analysts offering 12 month price targets for Taysha Gene Therapies Inc have a median target of 7.00, with a high estimate of 8.00 and a low estimate of 5.00. The median estimate represents a 329.45% increase from the last price of 1.63.
High390.8%8.00
Med329.4%7.00
Low206.7%5.00

Earnings history & estimates in USD

On Aug 12, 2024, Taysha Gene Therapies Inc reported 2nd quarter 2024 losses of -0.09 per share. This result exceeded the -0.17 consensus loss of the 11 analysts covering the company and exceeded last year's 2nd quarter results by 76.32%.
The next earnings announcement is expected on Nov 13, 2024.
Average growth rate-67.37%
Taysha Gene Therapies Inc reported annual 2023 losses of -0.96 per share on Mar 19, 2024.
Average growth rate+18.89%
More ▼

Revenue history & estimates in USD

Taysha Gene Therapies Inc had 2nd quarter 2024 revenues of 1.11m. This missed the 2.66m consensus estimate of the 11 analysts following the company. This was 76.37% below the prior year's 2nd quarter results.
Average growth rate+0.34%
Taysha Gene Therapies Inc had revenues for the full year 2023 of 15.45m. This was 517.55% above the prior year's results.
Average growth rate+258.77%
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.